Drug Profile
Research programme: hepatitis C therapies - Ligand
Alternative Names: LG-7501; LGD-7501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 30 Apr 2013 Preclinical development is ongoing in US
- 31 Dec 2011 Preclinical trials in Hepatitis C in USA (unspecified route)